• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Animal & Veterinary

  • Print
  • Share
  • E-mail

FDA Approves First Drug to Treat Urinary Incontinence in Female Dogs

July 27, 2011

The Food and Drug Administration today announced the approval of Incurin (estriol), the first drug approved for urinary incontinence in dogs. Incurin is indicated for the control of estrogen-responsive urinary incontinence in spayed female dogs.

Urinary incontinence (involuntary urine leakage) can be caused by different medical conditions. Hormone-based urinary incontinence is a common problem in middle-aged and elderly spayed female dogs. The pet can urinate normally, but they leak urine while resting. Frequently the dogs are not aware that they are leaking urine. Physical examination and blood and urine tests are usually normal in these pets. Hormone-responsive incontinence can occur months to years after a dog is spayed.

Incurin (estriol) is a natural estrogen hormone. Estrogens increase the resting muscle tone of the urethra in females and can be used to treat female dogs with urinary incontinence due to estrogen depletion.

In a placebo-controlled field study of 226 spayed female dogs, a greater percentage of dogs treated with Incurin were improved (fewer or no incontinence episodes) compared to dogs treated with placebo. Incurin was shown to be effective for the control of estrogen-responsive urinary incontinence in spayed female dogs 1 year of age and older.

The most common side effects associated with Incurin treatment included a loss of appetite, vomiting, excessive water drinking and swollen vulva.

Incurin is manufactured by Intervet, Inc. of Summit, New Jersey and will be made available through veterinarians at a later date.

 

Contact FDA

240-276-9300
240-276-9115 FAX
Issued by: FDA, Center for Veterinary Medicine

Communications Staff, HFV-12

7519 Standish Place

Rockville, MD 20855